CLL Support Association
9,239 members14,606 posts

iFCR Phase II Study Looks Promising

My wife, a younger, fit, otherwise healthy person diagnosed with CLL (unmutated IGHV, 11q deletion) began a Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia (iFCR) at Dana Farber in Boston. She just completed 1st month of treatment with remarkable results showing no side affects. WBC down from 50,000 to 6,000, "walnut sized" lymph nodes in neck now undetectable, "lime sized" nodes in abdomen that distended stomach "looking pregnant" reduced to point where her stomach is now flat. We begin 2nd of six monthly 3-day FCR infusions in two days, Ibrutinib pill continues daily for 8-month trial duration. We are optimistic that she will meet goal of trial, MRD negativity 2-months post treatment. She is sharing her treatment experience via webcast on Patient Power web site:

2 Replies


I'm so glad she is responding well to tx. Giving her cyber hugs and keep us updated on her progress.


1 like

Hi Itcbbaker,

I am so glad to hear that she is doing well. Was she offered the other trial ipi-145?

What made her decide to go with FCR/ibrutinib?

Was she told she only had to take the ibrutinib for 8 months or is it "lifetime" as long as you can tolerate it?

Best regards/God's speed to her and your family :)


You may also like...